<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250379</url>
  </required_header>
  <id_info>
    <org_study_id>MO22998</org_study_id>
    <secondary_id>2010-020998-16</secondary_id>
    <nct_id>NCT01250379</nct_id>
  </id_info>
  <brief_title>A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)</brief_title>
  <official_title>A Phase III Randomized Study Evaluating the Efficacy and Safety of Continued and Re-induced Bevacizumab in Combination With Chemotherapy for Patients With Locally Recurrent or Metastatic Breast Cancer After First-line Chemotherapy and Bevacizumab Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This randomized, open-label, parallel-group study will assess the efficacy and s afety of
      Avastin (bevacizumab) in combination with chemotherapy versus chemother apy alone as second-
      and third-line therapy in patients with locally recurrent o r metastatic breast cancer
      progressing after first-line therapy with Avastin and chemotherapy. Patients will be
      randomized to receive either Avastin (15 mg/kg e very 3 weeks or 10 mg/kg every 2 weeks
      intravenously) plus standard chemotherapy or chemotherapy alone. Anticipated time on study
      treatment is until third-line disease progression or unacceptable toxicity occurs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Second-Line Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)</measure>
    <time_frame>Baseline (less than or equal to [≤] 28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 3 years</time_frame>
    <description>Second-line PFS was defined as the time from randomization to progressive disease (PD) or death due to any cause during their second-line of treatment with bevacizumab and/or chemotherapy, whichever occurred first. For target lesions (TLs), PD was defined at least a 20 percent (%) increase in the sum of the largest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For non-target lesions (NTLs), PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Second-Line PFS</measure>
    <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 3 years</time_frame>
    <description>The median time, in months, from randomization to second-line PFS event. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Second-line PFS was defined as the time from randomization to PD or death due to any cause during their second-line of treatment with bevacizumab and/or chemotherapy, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Second-line PFS was defined as the time from randomization to PD or death due to any cause during their second-line of treatment with bevacizumab and/or chemotherapy, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without secondline PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 18</measure>
    <time_frame>Month 18</time_frame>
    <description>Second-line PFS was defined as the time from randomization to PD or death due to any cause during their secondline of treatment with bevacizumab and/or chemotherapy, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 24</measure>
    <time_frame>Month 24</time_frame>
    <description>Second-line PFS was defined as the time from randomization to PD or death due to any cause during their second-line of treatment with bevacizumab and/or chemotherapy, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Second-Line PFS by Baseline Risk Factor (Data Cutoff 20 December 2013)</measure>
    <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 3 years</time_frame>
    <description>The median time, in months, from randomization to second-line PFS event according to the following baseline risk factors: hormone receptor negative, HER2 negative (triple negative), hormone receptor positive/HER-2 negative (HR-pos/HER-neg), first-line PFS less than (&lt;) 6 months, first-line PFS greater than or equal to (≥) 6 months, taxane chemotherapy (chemo), non-taxane chemo, vinorelbine chemo, LDH ≤ 1.5 upper limit of normal (ULN), LDH greater than (&gt;) 1.5 ULN, &lt; 65 years of age, ≥ 65 years of age, &lt; 70 years of age, ≥ 70 years of age, &lt; 3 metastatic organ sites, ≥ 3 metastatic organ sites, bevacizumab-free (B-free) interval ≤ 6 weeks, B-free &gt; 6 weeks, disease-free (D-free) interval ≤ 24 months, D-free &gt; 24 months, D-free ≤ 12 months, and D-free &gt; 12 months. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented. PD: defined in Outcome measure 1. The 95% CI was estimated using Kaplan-Meier methodology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Second-Line Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) According to RECIST v1.1 (Data Cutoff 20 December 2013)</measure>
    <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 3 years</time_frame>
    <description>BOR was defined as a confirmed CR or PR during second-line treatment. For TLs, CR was defined as the disappearance of all TLs, and PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. The 95% Cl was determined using the Pearson-Clopper method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Second-Line CR, PR, Stable Disease, and PD According to RECIST v1.1 (Data Cutoff 20 December 2013)</measure>
    <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 3 years</time_frame>
    <description>For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD; SD was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; stable disease was defined as the persistence of 1 or more NTLs and/or maintenance of tumor marker levels above normal limits; and PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. The 95% CI was determined using the Pearson-Clopper method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Second-Line Objective Response (Data Cutoff 20 December 2013)</measure>
    <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 3 years</time_frame>
    <description>The median time, in months, from the date of the first second-line documentation of CR or PR according to RECIST v1.1 to the date of the first second-line documentation of PD or death due to any cause. For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels, and PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants with CR or PR who had experienced neither disease progression nor died were censored at the date of the last available tumor assessment when the participant was known to be progression free.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Second-Line Documented CR or PR According to RECIST v1.1 Estimated to be Alive and Free of Disease Progression at Months 3, 6, and 9 (Data Cutoff 20 December 2013)</measure>
    <time_frame>Months 3, 6, and 9</time_frame>
    <description>Duration of objective response was defined as the median time, in months, from the date of the first second-line documentation of CR or PR to the date of the first second-line documentation of PD or death due to any cause. For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels, and PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants with CR or PR who had experienced neither disease progression nor died were censored at the date of the last available tumor assessment when the participant was known to be progression free.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Third-Line PFS According to RECIST v1.1</measure>
    <time_frame>First dose of third-line treatment until PD or death due to any cause (assessed every 8-9 weeks, over a period of approximately 14 months)</time_frame>
    <description>Third-line PFS was defined as the time from the date of first dose of third-line bevacizumab and/or chemotherapy to the date of third-line PD or death due to any cause. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented. Participants without third-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Third-Line PFS</measure>
    <time_frame>First dose of third-line treatment until PD or death due to any cause (over a period of approximately 14 months)</time_frame>
    <description>The median time, in months, from the first dose of third-line bevacizumab and/or chemotherapy to third-line PD or death due to any cause. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without third-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Second- and Third-Line PFS According to RECIST v1.1</measure>
    <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 4 years</time_frame>
    <description>Second- and third-line PFS was defined as the time from the date randomization to the date of third-line PD or death due to any cause. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without third-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second- and Third-Line PFS</measure>
    <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 4 years</time_frame>
    <description>The median time, in months, from randomization to second-line and third-line PFS event. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without third-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Second- and Third-Line Tumor Progression</measure>
    <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 4 years</time_frame>
    <description>Second- and third-line tumor progression was defined as occurrence of third-line PD according to RECIST v1.1 or death due to progression of disease. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without third-line PD or death due to progression of disease were censored at the date of last tumor assessment where non-progression was documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Second- and Third-Line Tumor Progression</measure>
    <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 4 years</time_frame>
    <description>The median time, in months, from randomization to second- and third-line tumor progression. Second- and third-line tumor progression was defined as third-line PD according to RECIST v1.1 or death due to progression of disease. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without third-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Died</measure>
    <time_frame>Baseline until death (up to approximately 4 years)</time_frame>
    <description>Percentage of participants who died due to any reason were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline until death (up to approximately 4 years)</time_frame>
    <description>OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause. Participants who had not died were censored at the date the patient was last known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Estimated to be Surviving at Months 6, 12, 18, and 24</measure>
    <time_frame>Months 6, 12, 18, and 24</time_frame>
    <description>OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Problems by European Quality of Life Instrument (EQ-5D) Category (Data Cutoff 20 December 2013)</measure>
    <time_frame>Baseline, during second-line treatment at Weeks 8 and 16 (4-week cycles) or Weeks 9 and 18 (3-week cycles) and at second-line PD (up to approximately 3 years)</time_frame>
    <description>The EQ-5D is composed of 5 single-item measures where participants responded to questions assessing health status by responding with either &quot;no problems&quot;, &quot;some problems&quot;, or &quot;extreme problems&quot; in the following categories: mobility (M) (&quot;no problems&quot;=&quot;I have no problems in walking about&quot; to &quot;extreme problems&quot;=&quot;I am confined to bed&quot;), self-care (SC) (&quot;no problems&quot;=&quot;I have no problems with self-care&quot; to &quot;extreme problems&quot;=&quot;I am unable to wash or dress myself&quot;), usual activities (UA) (&quot;no problems&quot;=&quot;I have no problems performing my usual activities&quot; to &quot;extreme problems&quot;=&quot;I am unable to perform my usual activities&quot;), pain/discomfort (P/D) (&quot;no problems&quot;=&quot;I have no pain or discomfort&quot; to &quot;extreme problems&quot;=&quot;I have extreme pain or discomfort&quot;), and anxiety/depression (A/D) (&quot;no problems&quot;=&quot;I am not anxious or depressed&quot; to &quot;extreme problems&quot;='I am extremely anxious or depressed&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessed As an Index Score Using the EQ-5D (Data Cutoff 20 December 2013)</measure>
    <time_frame>Baseline, during second-line treatment at Weeks 8 and 16 (4-week cycles) or Weeks 9 and 18 (3-week cycles) and at second-line PD (up to approximately 3 years)</time_frame>
    <description>The EQ-5D is composed of 5 single-item measures where participants responded to questions assessing health status by responding with either &quot;no problems&quot;, &quot;some problems&quot;, or &quot;extreme problems&quot; in the following categories: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Based on large population surveys, an algorithm was used to combine the responses to each of these 5 measures into 1 single EQ-5D index score ranging from -0.59 (extreme problems) to +1 (no problems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D Index Scores (Data Cutoff 20 December 2013)</measure>
    <time_frame>Baseline, during second-line treatment at Weeks 8 and 16 (4-week cycles) or Weeks 9 and 18 (3-week cycles) and at second-line PD (up to approximately 3 years)</time_frame>
    <description>The EQ-5D is composed of 5 single-item measures where participants responded to questions assessing health status by responding with either &quot;no problems&quot;, &quot;some problems&quot;, or &quot;extreme problems&quot; in the following categories: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Based on large population surveys, an algorithm was used to combine the responses to each of these 5 measures into 1 single EQ-5D index score ranging from -0.59 (extreme problems) to +1 (no problems) where a negative value indicated a worsening of perceived quality of life and a positive value indicated an improvement of perceived quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessed Using the EQ-5D Visual Analogue Scale (VAS) Scores (Data Cutoff 20 December 2013)</measure>
    <time_frame>Baseline, during second-line treatment at Weeks 8 and 16 (4-week cycles) or Weeks 9 and 18 (3-week cycles) and at second-line PD (up to approximately 3 years)</time_frame>
    <description>The participant was asked to rate their overall health on a 0-100 millimeter (mm) vertical scale, where the lowest endpoint=0 (labeled as worst imaginable health state) and the highest endpoint =100 (labeled as the best imaginable health state). The participant marked the line corresponding to their assessment and the distance from the bottom was measured in millimeters. A higher value indicated a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in VAS Scores (Data Cutoff 20 December 2013)</measure>
    <time_frame>Baseline, during second-line treatment at Weeks 8 and 16 (4-week cycles) or Weeks 9 and 18 (3-week cycles) and at second-line PD (up to approximately 3 years)</time_frame>
    <description>The participant was asked to rate their overall health on a 0-100 mm vertical scale, where the lowest endpoint = 0 (labeled as worst imaginable health state) and the highest endpoint =100 (labeled as the best imaginable health state). The participant marked the line corresponding to their assessment and the distance from the bottom was measured in millimeters. A negative value indicated a worsening of perceived quality of life and a positive value indicated an improvement of perceived quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy-Breast (FACT-B) Scores (Data Cutoff 20 December 2013)</measure>
    <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter until second-line PD (up to approximately 3 years)</time_frame>
    <description>The Functional Assessment of Cancer Therapy-Breast (FACT-B) is composed of 5 multi-item sections where participants responded to questions assessing symptoms (scale: 0-4; 0=&quot;not at all&quot; and 4=&quot;very much&quot;), as follows: physical well-being (PWB) (7 items, total score 0-28), social/family well-being (SWB) (7 items, total score 0-28), emotional well-being (EWB) (6 items, total score 0-24), functional well-being (FWB) (7 items, total score 0-28); and breast cancer score based on the additional concerns section of FACT-B (10 items, total score 0-40). The FACT-B Trial Outcomes Index (TOI) score=sum of PWB, FWB, and breast cancer score subscale scores (total score 0-96). The Functional Assessment of Cancer Therapy-General (FACT-G) total score=sum of PWB, SWB, EWB, and FWB subscales scores (total score 0-108). The FACT-B total score=sum of PWB, SWB, EWB, FWB, and breast cancer score subscales scores (total score 0-148). In all cases a higher value indicated a better perceived quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FACT-B Scores (Data Cutoff 20 December 2013)</measure>
    <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter until second-line PD (up to approximately 3 years)</time_frame>
    <description>The FACT-B is composed of 5 multi-item sections where participants responded to questions assessing symptoms (scale: 0-4; 0=&quot;not at all&quot; and 4=&quot;very much&quot;), as follows: PWB (7 items, total score 0-28), SWB (7 items, total score 0-28), EWB (6 items, total score 0-24), FWB (7 items, total score 0-28); and breast cancer score based on the additional concerns section of FACT-B (10 items, total score 0-40). The FACT-B TOI score=sum of PWB, FWB, and breast cancer score subscale scores (total score 0-96). The FACT-G total score=sum of PWB, SWB, EWB, and FWB subscales scores (total score 0-108). The FACT-B total score=sum of PWB, SWB, EWB, FWB, and breast cancer score subscale scores (total score 0-148). In all cases a higher value indicated a better perceived quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">494</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab [Avastin]</intervention_name>
    <description>10 mg/ kg iv every 2 weeks or 15 mg/kg iv every 3 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Standard chemotherapy (doublets not allowed)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients, &gt;/= 18 years of age

          -  Histologically confirmed HER2-negative breast cancer

          -  Disease progression during or following first-line treatment with Avastin and
             chemotherapy for locally recurrent or metastatic breast cancer

          -  Avastin treatment in first-line setting must have been a minimum of 4 cycles (15
             mg/kg) or 6 cycles (10 mg/kg) in combination with chemotherapy

          -  ECOG performance status 0-2

          -  At least 28 days since prior radiation therapy or surgery and recovery from treatment

        Exclusion Criteria:

          -  Anti-angiogenic therapy or anti-vascular endothelial growth factors other than Avastin
             for first-line treatment

          -  Active malignancy other than superficial basal cell and superficial squamous cell
             carcinoma of the skin, or in situ carcinoma of the cervix or breast within the last 5
             years

          -  Inadequate renal function

          -  Clinically relevant cardio-vascular disease

          -  Known CNS disease except for treated brain metastases

          -  Chronic daily treatment with high-dose aspirin (&gt;325 mg/day) or clopidogrel (&gt;75
             mg/day)

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1199ACI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>T4000IAK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Feldkirch</city>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krems</city>
        <zip>3500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Steyr</city>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villach</city>
        <zip>9500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <zip>74140-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90430-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Itajai</city>
        <state>SC</state>
        <zip>88301-220</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amiens</city>
        <zip>80090</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boulogne Sur Mer</city>
        <zip>62222</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grenoble</city>
        <zip>38028</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limoges</city>
        <zip>87039</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nancy</city>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reims CEDEX</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Gregoire</city>
        <zip>35768</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Jean</city>
        <zip>31240</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Priest En Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Quentin</city>
        <zip>02321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amberg</city>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10719</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bielefeld</city>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chemnitz</city>
        <zip>09116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <zip>40235</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <zip>79110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göttingen</city>
        <zip>37073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <zip>30177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlsruhe</city>
        <zip>76135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koeln</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <zip>68161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <zip>80639</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naunhof</city>
        <zip>04683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <zip>41462</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nordhausen</city>
        <zip>99734</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osnabrueck</city>
        <zip>49076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ravensburg</city>
        <zip>88212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stade</city>
        <zip>21680</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stralsund</city>
        <zip>18435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ioannina</city>
        <zip>455 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Patras</city>
        <zip>265 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <zip>546 45</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar-Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat Gan</city>
        <zip>52620-00</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rehovot</city>
        <zip>7610001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cosenza</city>
        <state>Calabria</state>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Benevento</city>
        <state>Campania</state>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reggio Emilia</city>
        <state>Emilia-Romagna</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Udine</city>
        <state>Friuli-Venezia Giulia</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monza</city>
        <state>Lombardia</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Macerata</city>
        <state>Marche</state>
        <zip>62100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sassari</city>
        <state>Sardegna</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pontedera</city>
        <state>Toscana</state>
        <zip>56025</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardejov</city>
        <zip>085 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <zip>812 50</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kosice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nove Zamky</city>
        <zip>940 34</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Presov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Sebastian</city>
        <state>Guipuzcoa</state>
        <zip>20080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Castellon</city>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leon</city>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lerida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aarau</city>
        <zip>5000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zürich</city>
        <zip>8038</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2010</study_first_submitted>
  <study_first_submitted_qc>November 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2010</study_first_posted>
  <results_first_submitted>June 5, 2015</results_first_submitted>
  <results_first_submitted_qc>June 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 30, 2015</results_first_posted>
  <last_update_submitted>January 12, 2016</last_update_submitted>
  <last_update_submitted_qc>January 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 556 participants were screened and of these, 494 were randomized.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Chemotherapy (CT) Arm</title>
          <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
        </group>
        <group group_id="P2">
          <title>Chemotherapy Plus Bevacizumab (CT+BV) Arm</title>
          <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 milligrams per kilogram (mg/kg), intravenously (IV), every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="247"/>
                <participants group_id="P2" count="247"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45">Participants under study follow-up as of Data Cutoff 30 April 2015 were considered as completers.</participants>
                <participants group_id="P2" count="54">Participants under study follow-up as of Data Cutoff 30 April 2015 were considered as completers.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="193"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="148"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population: all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>CT Arm</title>
          <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
        </group>
        <group group_id="B2">
          <title>CT+BV Arm</title>
          <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="247"/>
            <count group_id="B2" value="247"/>
            <count group_id="B3" value="494"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.7" spread="10.83"/>
                    <measurement group_id="B2" value="55.8" spread="11.17"/>
                    <measurement group_id="B3" value="55.2" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="247"/>
                    <measurement group_id="B3" value="494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Second-Line Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)</title>
        <description>Second-line PFS was defined as the time from randomization to progressive disease (PD) or death due to any cause during their second-line of treatment with bevacizumab and/or chemotherapy, whichever occurred first. For target lesions (TLs), PD was defined at least a 20 percent (%) increase in the sum of the largest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For non-target lesions (NTLs), PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
        <time_frame>Baseline (less than or equal to [≤] 28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 3 years</time_frame>
        <population>Intent-to-Treat (ITT) population - all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Second-Line Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)</title>
          <description>Second-line PFS was defined as the time from randomization to progressive disease (PD) or death due to any cause during their second-line of treatment with bevacizumab and/or chemotherapy, whichever occurred first. For target lesions (TLs), PD was defined at least a 20 percent (%) increase in the sum of the largest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For non-target lesions (NTLs), PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
          <population>Intent-to-Treat (ITT) population - all randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7"/>
                    <measurement group_id="O2" value="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Second-Line PFS</title>
        <description>The median time, in months, from randomization to second-line PFS event. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
        <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 3 years</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Second-Line PFS</title>
          <description>The median time, in months, from randomization to second-line PFS event. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
          <population>ITT population</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.9" upper_limit="5.3"/>
                    <measurement group_id="O2" value="6.3" lower_limit="5.5" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0204</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
            <estimate_desc>The 95% confidence interval (CI) was estimated using Cox proportional hazards methodology. The stratification factors used in the analysis were hormone receptor status, first-line PFS, choice of chemotherapy, and lactate dehydrogenase (LDH) level.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0245</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
            <estimate_desc>Unstratified analysis.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Second-Line PFS by Baseline Risk Factor (Data Cutoff 20 December 2013)</title>
        <description>The median time, in months, from randomization to second-line PFS event according to the following baseline risk factors: hormone receptor negative, HER2 negative (triple negative), hormone receptor positive/HER-2 negative (HR-pos/HER-neg), first-line PFS less than (&lt;) 6 months, first-line PFS greater than or equal to (≥) 6 months, taxane chemotherapy (chemo), non-taxane chemo, vinorelbine chemo, LDH ≤ 1.5 upper limit of normal (ULN), LDH greater than (&gt;) 1.5 ULN, &lt; 65 years of age, ≥ 65 years of age, &lt; 70 years of age, ≥ 70 years of age, &lt; 3 metastatic organ sites, ≥ 3 metastatic organ sites, bevacizumab-free (B-free) interval ≤ 6 weeks, B-free &gt; 6 weeks, disease-free (D-free) interval ≤ 24 months, D-free &gt; 24 months, D-free ≤ 12 months, and D-free &gt; 12 months. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented. PD: defined in Outcome measure 1. The 95% CI was estimated using Kaplan-Meier methodology.</description>
        <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 3 years</time_frame>
        <population>ITT population. Here, Number of participants analyzed equals (=) participants evaluable for this outcome measure and number (n) = number of participants included in the analysis for the specified risk factor.</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Second-Line PFS by Baseline Risk Factor (Data Cutoff 20 December 2013)</title>
          <description>The median time, in months, from randomization to second-line PFS event according to the following baseline risk factors: hormone receptor negative, HER2 negative (triple negative), hormone receptor positive/HER-2 negative (HR-pos/HER-neg), first-line PFS less than (&lt;) 6 months, first-line PFS greater than or equal to (≥) 6 months, taxane chemotherapy (chemo), non-taxane chemo, vinorelbine chemo, LDH ≤ 1.5 upper limit of normal (ULN), LDH greater than (&gt;) 1.5 ULN, &lt; 65 years of age, ≥ 65 years of age, &lt; 70 years of age, ≥ 70 years of age, &lt; 3 metastatic organ sites, ≥ 3 metastatic organ sites, bevacizumab-free (B-free) interval ≤ 6 weeks, B-free &gt; 6 weeks, disease-free (D-free) interval ≤ 24 months, D-free &gt; 24 months, D-free ≤ 12 months, and D-free &gt; 12 months. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented. PD: defined in Outcome measure 1. The 95% CI was estimated using Kaplan-Meier methodology.</description>
          <population>ITT population. Here, Number of participants analyzed equals (=) participants evaluable for this outcome measure and number (n) = number of participants included in the analysis for the specified risk factor.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HR-neg (n=60,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="2.0" upper_limit="3.9"/>
                    <measurement group_id="O2" value="4.9" lower_limit="3.4" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR-pos/HER-neg (n=187,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="4.2" upper_limit="6.2"/>
                    <measurement group_id="O2" value="6.7" lower_limit="6.0" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PFS &lt;6 months (n=69,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="2.3" upper_limit="4.3"/>
                    <measurement group_id="O2" value="5.1" lower_limit="4.1" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PFS ≥6 months (n=178,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="3.9" upper_limit="6.1"/>
                    <measurement group_id="O2" value="6.4" lower_limit="5.8" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taxane chemo (n=32,32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="1.7" upper_limit="5.3"/>
                    <measurement group_id="O2" value="6.9" lower_limit="4.9" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-taxane chemo (n=191,188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="3.9" upper_limit="5.8"/>
                    <measurement group_id="O2" value="6.0" lower_limit="4.9" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vinorelbine chemo (n=24,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.8" upper_limit="4.3"/>
                    <measurement group_id="O2" value="6.5" lower_limit="4.2" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDH ≤ 1.5 ULN (n=207,210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="3.9" upper_limit="6.0"/>
                    <measurement group_id="O2" value="6.3" lower_limit="5.5" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDH &gt; 1.5 ULN (n=40,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.7" upper_limit="3.9"/>
                    <measurement group_id="O2" value="5.8" lower_limit="2.5" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 65 years of age (n=196,183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.9" upper_limit="4.7"/>
                    <measurement group_id="O2" value="6.1" lower_limit="4.7" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 65 years of age (n=51,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="2.2" upper_limit="7.8"/>
                    <measurement group_id="O2" value="6.7" lower_limit="5.5" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 70 years of age (n=226,219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.7" upper_limit="4.6"/>
                    <measurement group_id="O2" value="6.2" lower_limit="5.3" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 70 years of age (n=21,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="2.2" upper_limit="11.9"/>
                    <measurement group_id="O2" value="6.7" lower_limit="4.1" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 3 metastatic organ sites (n=158,167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.9" upper_limit="6.1"/>
                    <measurement group_id="O2" value="6.9" lower_limit="6.0" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3 metastatic organ sites (n=88,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2.1" upper_limit="4.9"/>
                    <measurement group_id="O2" value="4.7" lower_limit="4.1" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-free ≤ 6 weeks (n=165,149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.6" upper_limit="4.6"/>
                    <measurement group_id="O2" value="5.8" lower_limit="4.4" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-free &gt; 6 weeks (n=81,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="3.3" upper_limit="6.3"/>
                    <measurement group_id="O2" value="7.6" lower_limit="6.0" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-free ≤ 24 months (n=58,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.0" upper_limit="3.9"/>
                    <measurement group_id="O2" value="5.8" lower_limit="4.2" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-free &gt; 24 months (n=138,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="4.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="6.5" lower_limit="5.5" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-free ≤ 12 months (n=24,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.3" upper_limit="5.8"/>
                    <measurement group_id="O2" value="5.8" lower_limit="3.9" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-free &gt; 12 months (n=172,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="3.9" upper_limit="5.7"/>
                    <measurement group_id="O2" value="6.3" lower_limit="5.3" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: HR-neg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0088</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: HR-pos/HER-neg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1196</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: PFS &lt;6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0110</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: PFS ≥6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0816</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: taxane chemo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0395</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: non-taxane chemo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1385</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: vinorelbine chemo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0029</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: LDH ≤ 1.5 ULN</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0171</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: LDH &gt; 1.5 ULN</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1797</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: &lt; 65 years of age</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0229</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: ≥ 65 years of age</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2139</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: &lt; 70 years of age</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0021</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: ≥ 70 years of age</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5216</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: &lt; 3 metastatic organ sites</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0148</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: ≥ 3 metastatic organ sites</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3102</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: B-free ≤ 6 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0967</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: B-free &gt; 6 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0489</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: D-free ≤ 24 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0176</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: D-free &gt; 24 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2318</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: D-free ≤ 12 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0568</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subgroup analysis: D-free &gt; 12 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1143</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Second-Line Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) According to RECIST v1.1 (Data Cutoff 20 December 2013)</title>
        <description>BOR was defined as a confirmed CR or PR during second-line treatment. For TLs, CR was defined as the disappearance of all TLs, and PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. The 95% Cl was determined using the Pearson-Clopper method.</description>
        <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 3 years</time_frame>
        <population>ITT population; only randomized participants with measurable disease at baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Second-Line Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) According to RECIST v1.1 (Data Cutoff 20 December 2013)</title>
          <description>BOR was defined as a confirmed CR or PR during second-line treatment. For TLs, CR was defined as the disappearance of all TLs, and PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. The 95% Cl was determined using the Pearson-Clopper method.</description>
          <population>ITT population; only randomized participants with measurable disease at baseline were included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" lower_limit="11.7" upper_limit="22.9"/>
                    <measurement group_id="O2" value="20.9" lower_limit="15.2" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3457</p_value>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>12.4</ci_upper_limit>
            <estimate_desc>The 95% CI was estimated using Hauck-Anderson methodology.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Second-Line CR, PR, Stable Disease, and PD According to RECIST v1.1 (Data Cutoff 20 December 2013)</title>
        <description>For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD; SD was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; stable disease was defined as the persistence of 1 or more NTLs and/or maintenance of tumor marker levels above normal limits; and PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. The 95% CI was determined using the Pearson-Clopper method.</description>
        <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 3 years</time_frame>
        <population>ITT population; only randomized participants with measurable disease at baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Second-Line CR, PR, Stable Disease, and PD According to RECIST v1.1 (Data Cutoff 20 December 2013)</title>
          <description>For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD; SD was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; stable disease was defined as the persistence of 1 or more NTLs and/or maintenance of tumor marker levels above normal limits; and PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. The 95% CI was determined using the Pearson-Clopper method.</description>
          <population>ITT population; only randomized participants with measurable disease at baseline were included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.1" upper_limit="3.9"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" lower_limit="10.8" upper_limit="21.7"/>
                    <measurement group_id="O2" value="20.3" lower_limit="14.7" upper_limit="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" lower_limit="26.8" upper_limit="40.8"/>
                    <measurement group_id="O2" value="48.9" lower_limit="41.4" upper_limit="56.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" lower_limit="33.9" upper_limit="48.5"/>
                    <measurement group_id="O2" value="24.2" lower_limit="18.1" upper_limit="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to assess</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="5.0" upper_limit="13.7"/>
                    <measurement group_id="O2" value="6.0" lower_limit="3.1" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Second-Line Objective Response (Data Cutoff 20 December 2013)</title>
        <description>The median time, in months, from the date of the first second-line documentation of CR or PR according to RECIST v1.1 to the date of the first second-line documentation of PD or death due to any cause. For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels, and PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants with CR or PR who had experienced neither disease progression nor died were censored at the date of the last available tumor assessment when the participant was known to be progression free.</description>
        <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 3 years</time_frame>
        <population>ITT population; only randomized participants with a CR or PR were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Second-Line Objective Response (Data Cutoff 20 December 2013)</title>
          <description>The median time, in months, from the date of the first second-line documentation of CR or PR according to RECIST v1.1 to the date of the first second-line documentation of PD or death due to any cause. For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels, and PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants with CR or PR who had experienced neither disease progression nor died were censored at the date of the last available tumor assessment when the participant was known to be progression free.</description>
          <population>ITT population; only randomized participants with a CR or PR were included in the analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="4.4" upper_limit="16.7"/>
                    <measurement group_id="O2" value="8.3" lower_limit="6.1" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9825</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.99</ci_upper_limit>
            <estimate_desc>The 95% CI was estimated using Cox proportional hazards methodology. The stratification factors used in stratified analysis were hormone receptor status, first-line PFS, choice of chemotherapy, and LDH level.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3601</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>2.34</ci_upper_limit>
            <estimate_desc>Unstratified analysis.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Second-Line Documented CR or PR According to RECIST v1.1 Estimated to be Alive and Free of Disease Progression at Months 3, 6, and 9 (Data Cutoff 20 December 2013)</title>
        <description>Duration of objective response was defined as the median time, in months, from the date of the first second-line documentation of CR or PR to the date of the first second-line documentation of PD or death due to any cause. For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels, and PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants with CR or PR who had experienced neither disease progression nor died were censored at the date of the last available tumor assessment when the participant was known to be progression free.</description>
        <time_frame>Months 3, 6, and 9</time_frame>
        <population>ITT population; only randomized participants with a CR or PR were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Second-Line Documented CR or PR According to RECIST v1.1 Estimated to be Alive and Free of Disease Progression at Months 3, 6, and 9 (Data Cutoff 20 December 2013)</title>
          <description>Duration of objective response was defined as the median time, in months, from the date of the first second-line documentation of CR or PR to the date of the first second-line documentation of PD or death due to any cause. For TLs, CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels, and PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants with CR or PR who had experienced neither disease progression nor died were censored at the date of the last available tumor assessment when the participant was known to be progression free.</description>
          <population>ITT population; only randomized participants with a CR or PR were included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="78.6" upper_limit="99.5"/>
                    <measurement group_id="O2" value="100.0">95% CI data was not applicable (NA) because all participants were estimated to be alive and free of disease progression at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" lower_limit="48.9" upper_limit="82.5"/>
                    <measurement group_id="O2" value="72.8" lower_limit="55.3" upper_limit="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9" lower_limit="40.4" upper_limit="76.3"/>
                    <measurement group_id="O2" value="40.8" lower_limit="24.6" upper_limit="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Third-Line PFS According to RECIST v1.1</title>
        <description>Third-line PFS was defined as the time from the date of first dose of third-line bevacizumab and/or chemotherapy to the date of third-line PD or death due to any cause. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented. Participants without third-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
        <time_frame>First dose of third-line treatment until PD or death due to any cause (assessed every 8-9 weeks, over a period of approximately 14 months)</time_frame>
        <population>Third line ITT population: all randomized participants who received third-line treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Third-Line PFS According to RECIST v1.1</title>
          <description>Third-line PFS was defined as the time from the date of first dose of third-line bevacizumab and/or chemotherapy to the date of third-line PD or death due to any cause. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented. Participants without third-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
          <population>Third line ITT population: all randomized participants who received third-line treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3"/>
                    <measurement group_id="O2" value="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Third-Line PFS</title>
        <description>The median time, in months, from the first dose of third-line bevacizumab and/or chemotherapy to third-line PD or death due to any cause. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without third-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
        <time_frame>First dose of third-line treatment until PD or death due to any cause (over a period of approximately 14 months)</time_frame>
        <population>Third line ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Third-Line PFS</title>
          <description>The median time, in months, from the first dose of third-line bevacizumab and/or chemotherapy to third-line PD or death due to any cause. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without third-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
          <population>Third line ITT population</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.2" upper_limit="3.9"/>
                    <measurement group_id="O2" value="3.8" lower_limit="2.4" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1080</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>The 95% CI was estimated using Cox proportional hazards methodology. The stratification factors used in stratified analysis were hormone receptor status, first-line PFS, choice of chemotherapy, and LDH level.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0625</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>Unstratified analysis.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Second- and Third-Line PFS According to RECIST v1.1</title>
        <description>Second- and third-line PFS was defined as the time from the date randomization to the date of third-line PD or death due to any cause. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without third-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
        <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 4 years</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Second- and Third-Line PFS According to RECIST v1.1</title>
          <description>Second- and third-line PFS was defined as the time from the date randomization to the date of third-line PD or death due to any cause. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without third-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7"/>
                    <measurement group_id="O2" value="83.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Second- and Third-Line PFS</title>
        <description>The median time, in months, from randomization to second-line and third-line PFS event. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without third-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
        <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 4 years</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Second- and Third-Line PFS</title>
          <description>The median time, in months, from randomization to second-line and third-line PFS event. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without third-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
          <population>ITT population</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="9.2" upper_limit="12.5"/>
                    <measurement group_id="O2" value="12.8" lower_limit="10.7" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1349</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>The 95% CI was estimated using Cox proportional hazards methodology. The stratification factors used in stratified analysis were hormone receptor status, first-line PFS, choice of chemotherapy, and LDH level.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0863</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>Unstratified analysis.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Second- and Third-Line Tumor Progression</title>
        <description>Second- and third-line tumor progression was defined as occurrence of third-line PD according to RECIST v1.1 or death due to progression of disease. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without third-line PD or death due to progression of disease were censored at the date of last tumor assessment where non-progression was documented.</description>
        <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 4 years</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Second- and Third-Line Tumor Progression</title>
          <description>Second- and third-line tumor progression was defined as occurrence of third-line PD according to RECIST v1.1 or death due to progression of disease. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without third-line PD or death due to progression of disease were censored at the date of last tumor assessment where non-progression was documented.</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2"/>
                    <measurement group_id="O2" value="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Second- and Third-Line Tumor Progression</title>
        <description>The median time, in months, from randomization to second- and third-line tumor progression. Second­ and third­line tumor progression was defined as third­line PD according to RECIST v1.1 or death due to progression of disease. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without third-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
        <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 4 years</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Second- and Third-Line Tumor Progression</title>
          <description>The median time, in months, from randomization to second- and third-line tumor progression. Second­ and third­line tumor progression was defined as third­line PD according to RECIST v1.1 or death due to progression of disease. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without third-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
          <population>ITT population</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="9.4" upper_limit="12.7"/>
                    <measurement group_id="O2" value="13.3" lower_limit="12.0" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0744</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>The 95% CI was estimated using Cox proportional hazards methodology. The stratification factors used in stratified analysis were hormone receptor status, first-line PFS, choice of chemotherapy, and LDH level.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0503</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>Unstratified analysis.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 6</title>
        <description>Second-line PFS was defined as the time from randomization to PD or death due to any cause during their second-line of treatment with bevacizumab and/or chemotherapy, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
        <time_frame>Month 6</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 6</title>
          <description>Second-line PFS was defined as the time from randomization to PD or death due to any cause during their second-line of treatment with bevacizumab and/or chemotherapy, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented.</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" lower_limit="34.3" upper_limit="47.0"/>
                    <measurement group_id="O2" value="54.2" lower_limit="47.7" upper_limit="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Died</title>
        <description>Percentage of participants who died due to any reason were reported.</description>
        <time_frame>Baseline until death (up to approximately 4 years)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Died</title>
          <description>Percentage of participants who died due to any reason were reported.</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2"/>
                    <measurement group_id="O2" value="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause. Participants who had not died were censored at the date the patient was last known to be alive.</description>
        <time_frame>Baseline until death (up to approximately 4 years)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause. Participants who had not died were censored at the date the patient was last known to be alive.</description>
          <population>ITT population</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="15.4" upper_limit="21.2"/>
                    <measurement group_id="O2" value="19.7" lower_limit="17.6" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7253</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>The 95% CI was estimated using Cox proportional hazards methodology. The stratification factors used in stratified analysis were hormone receptor status, first-line PFS, choice of chemotherapy, and LDH level.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5332</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>Unstratified analysis.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Estimated to be Surviving at Months 6, 12, 18, and 24</title>
        <description>OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause.</description>
        <time_frame>Months 6, 12, 18, and 24</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Estimated to be Surviving at Months 6, 12, 18, and 24</title>
          <description>OS was defined as the median time, in months, from the date of randomization to the date of death, due to any cause.</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.2" lower_limit="79.9" upper_limit="89.2"/>
                    <measurement group_id="O2" value="90.4" lower_limit="85.9" upper_limit="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6" lower_limit="62.0" upper_limit="74.3"/>
                    <measurement group_id="O2" value="72.4" lower_limit="66.2" upper_limit="77.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" lower_limit="46.0" upper_limit="59.3"/>
                    <measurement group_id="O2" value="54.9" lower_limit="48.2" upper_limit="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.4" lower_limit="31.8" upper_limit="44.9"/>
                    <measurement group_id="O2" value="37.6" lower_limit="31.3" upper_limit="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Problems by European Quality of Life Instrument (EQ-5D) Category (Data Cutoff 20 December 2013)</title>
        <description>The EQ-5D is composed of 5 single-item measures where participants responded to questions assessing health status by responding with either “no problems”, “some problems”, or “extreme problems” in the following categories: mobility (M) (“no problems”=“I have no problems in walking about” to “extreme problems”=“I am confined to bed”), self-care (SC) (“no problems”=“I have no problems with self-care” to “extreme problems”=”I am unable to wash or dress myself”), usual activities (UA) (“no problems”=“I have no problems performing my usual activities” to “extreme problems”=“I am unable to perform my usual activities”), pain/discomfort (P/D) (“no problems”=“I have no pain or discomfort” to “extreme problems”=“I have extreme pain or discomfort”), and anxiety/depression (A/D) (“no problems”=“I am not anxious or depressed” to “extreme problems”=‘I am extremely anxious or depressed”).</description>
        <time_frame>Baseline, during second-line treatment at Weeks 8 and 16 (4-week cycles) or Weeks 9 and 18 (3-week cycles) and at second-line PD (up to approximately 3 years)</time_frame>
        <population>ITT population. Here, Number of participants analyzed = participants evaluable for this outcome measure and n=number of participants completing the questionnaires at the corresponding timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Problems by European Quality of Life Instrument (EQ-5D) Category (Data Cutoff 20 December 2013)</title>
          <description>The EQ-5D is composed of 5 single-item measures where participants responded to questions assessing health status by responding with either “no problems”, “some problems”, or “extreme problems” in the following categories: mobility (M) (“no problems”=“I have no problems in walking about” to “extreme problems”=“I am confined to bed”), self-care (SC) (“no problems”=“I have no problems with self-care” to “extreme problems”=”I am unable to wash or dress myself”), usual activities (UA) (“no problems”=“I have no problems performing my usual activities” to “extreme problems”=“I am unable to perform my usual activities”), pain/discomfort (P/D) (“no problems”=“I have no pain or discomfort” to “extreme problems”=“I have extreme pain or discomfort”), and anxiety/depression (A/D) (“no problems”=“I am not anxious or depressed” to “extreme problems”=‘I am extremely anxious or depressed”).</description>
          <population>ITT population. Here, Number of participants analyzed = participants evaluable for this outcome measure and n=number of participants completing the questionnaires at the corresponding timepoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL: M, no problems (n=214,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3"/>
                    <measurement group_id="O2" value="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: M, some problems (n=214,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4"/>
                    <measurement group_id="O2" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: M, extreme problems (n=214,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: SC, no problems (n=214,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7"/>
                    <measurement group_id="O2" value="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: SC, some problems (n=214,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                    <measurement group_id="O2" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: SC, extreme problems (n=214,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: UA, no problems (n=214,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7"/>
                    <measurement group_id="O2" value="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: UA, some problems (n=214,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2"/>
                    <measurement group_id="O2" value="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: UA, extreme problems (n=214,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: P/D, no problems (n=214,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3"/>
                    <measurement group_id="O2" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: P/D, some problems (n=214,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.7"/>
                    <measurement group_id="O2" value="66.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: P/D, extreme problems (n=214,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: A/D, no problems (n=214,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6"/>
                    <measurement group_id="O2" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: A/D, some problems (n=214,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5"/>
                    <measurement group_id="O2" value="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: A/D, extreme problems (n=214,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: M, no problems (n=133,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7"/>
                    <measurement group_id="O2" value="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: M, some problems (n=133,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6"/>
                    <measurement group_id="O2" value="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: M, extreme problems (n=133,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: SC, no problems (n=133,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.0"/>
                    <measurement group_id="O2" value="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: SC, some problems (n=133,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5"/>
                    <measurement group_id="O2" value="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: SC, extreme problems (n=133,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: UA, no problems (n=133,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.4"/>
                    <measurement group_id="O2" value="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: UA, some problems (n=133,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6"/>
                    <measurement group_id="O2" value="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: UA, extreme problems (n=133,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: P/D, no problems (n=133,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3"/>
                    <measurement group_id="O2" value="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: P/D, some problems (n=133,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7"/>
                    <measurement group_id="O2" value="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: P/D, extreme problems (n=133,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: A/D, no problems (n=133,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.6"/>
                    <measurement group_id="O2" value="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: A/D, some problems (n=133,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6"/>
                    <measurement group_id="O2" value="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: A/D, extreme problems (n=133,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: M, no problems (n=84,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="49.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: M, some problems (n=84,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8"/>
                    <measurement group_id="O2" value="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: M, extreme problems (n=84,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: SC, no problems (n=84,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0"/>
                    <measurement group_id="O2" value="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: SC, some problems (n=84,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: SC, extreme problems (n=84,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: UA, no problems (n=84,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: UA, some problems (n=84,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: UA, extreme problems (n=84,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: P/D, no problems (n=84,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5"/>
                    <measurement group_id="O2" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: P/D, some problems (n=84,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5"/>
                    <measurement group_id="O2" value="76.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: P/D, extreme problems (n=84,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: A/D, no problems (n=84,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2"/>
                    <measurement group_id="O2" value="49.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: A/D, some problems (n=84,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0"/>
                    <measurement group_id="O2" value="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: A/D, extreme problems (n=84,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD: M, no problems (n=82,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8"/>
                    <measurement group_id="O2" value="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD: M, some problems (n=82,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1"/>
                    <measurement group_id="O2" value="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD: M, extreme problems (n=82,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD: SC, no problems (n=82,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.8"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD: SC, some problems (n=82,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                    <measurement group_id="O2" value="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD: SC, extreme problems (n=82,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD: UA, no problems (n=82,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0"/>
                    <measurement group_id="O2" value="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD: UA, some problems (n=82,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD: UA, extreme problems (n=82,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD: P/D, no problems (n=82,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5"/>
                    <measurement group_id="O2" value="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD: P/D, some problems (n=82,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1"/>
                    <measurement group_id="O2" value="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD: P/D, extreme problems (n=82,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5"/>
                    <measurement group_id="O2" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD: A/D, no problems (n=82,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6"/>
                    <measurement group_id="O2" value="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD: A/D, some problems (n=82,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD: A/D, extreme problems (n=82,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Assessed As an Index Score Using the EQ-5D (Data Cutoff 20 December 2013)</title>
        <description>The EQ-5D is composed of 5 single-item measures where participants responded to questions assessing health status by responding with either “no problems”, “some problems”, or “extreme problems” in the following categories: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Based on large population surveys, an algorithm was used to combine the responses to each of these 5 measures into 1 single EQ-5D index score ranging from -0.59 (extreme problems) to +1 (no problems).</description>
        <time_frame>Baseline, during second-line treatment at Weeks 8 and 16 (4-week cycles) or Weeks 9 and 18 (3-week cycles) and at second-line PD (up to approximately 3 years)</time_frame>
        <population>ITT population. Here, Number of participants analyzed = participants evaluable for this outcome measure and n=number of participants who completed the assessment at the specified timepoint</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Assessed As an Index Score Using the EQ-5D (Data Cutoff 20 December 2013)</title>
          <description>The EQ-5D is composed of 5 single-item measures where participants responded to questions assessing health status by responding with either “no problems”, “some problems”, or “extreme problems” in the following categories: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Based on large population surveys, an algorithm was used to combine the responses to each of these 5 measures into 1 single EQ-5D index score ranging from -0.59 (extreme problems) to +1 (no problems).</description>
          <population>ITT population. Here, Number of participants analyzed = participants evaluable for this outcome measure and n=number of participants who completed the assessment at the specified timepoint</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (n=202,219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6806" lower_limit="0.6489" upper_limit="0.7122"/>
                    <measurement group_id="O2" value="0.6725" lower_limit="0.6389" upper_limit="0.7061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9 (n=127,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6953" lower_limit="0.6470" upper_limit="0.7437"/>
                    <measurement group_id="O2" value="0.6515" lower_limit="0.6057" upper_limit="0.6973"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18 (n=80,118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7496" lower_limit="0.7114" upper_limit="0.7879"/>
                    <measurement group_id="O2" value="0.6534" lower_limit="0.6058" upper_limit="0.7010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD (n=77,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6290" lower_limit="0.5642" upper_limit="0.6938"/>
                    <measurement group_id="O2" value="0.5553" lower_limit="0.4736" upper_limit="0.6370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D Index Scores (Data Cutoff 20 December 2013)</title>
        <description>The EQ-5D is composed of 5 single-item measures where participants responded to questions assessing health status by responding with either &quot;no problems&quot;, &quot;some problems&quot;, or &quot;extreme problems&quot; in the following categories: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Based on large population surveys, an algorithm was used to combine the responses to each of these 5 measures into 1 single EQ-5D index score ranging from -0.59 (extreme problems) to +1 (no problems) where a negative value indicated a worsening of perceived quality of life and a positive value indicated an improvement of perceived quality of life.</description>
        <time_frame>Baseline, during second-line treatment at Weeks 8 and 16 (4-week cycles) or Weeks 9 and 18 (3-week cycles) and at second-line PD (up to approximately 3 years)</time_frame>
        <population>ITT population. Here, Number of participants analyzed = participants evaluable for this outcome measure and n=number of participants who completed the assessment at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D Index Scores (Data Cutoff 20 December 2013)</title>
          <description>The EQ-5D is composed of 5 single-item measures where participants responded to questions assessing health status by responding with either &quot;no problems&quot;, &quot;some problems&quot;, or &quot;extreme problems&quot; in the following categories: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Based on large population surveys, an algorithm was used to combine the responses to each of these 5 measures into 1 single EQ-5D index score ranging from -0.59 (extreme problems) to +1 (no problems) where a negative value indicated a worsening of perceived quality of life and a positive value indicated an improvement of perceived quality of life.</description>
          <population>ITT population. Here, Number of participants analyzed = participants evaluable for this outcome measure and n=number of participants who completed the assessment at the specified timepoint.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8/9 (n=107,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0103" lower_limit="-0.0482" upper_limit="0.0276"/>
                    <measurement group_id="O2" value="-0.0370" lower_limit="-0.0868" upper_limit="0.0127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18 (n=68,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0387" lower_limit="-0.0025" upper_limit="0.0800"/>
                    <measurement group_id="O2" value="-0.0508" lower_limit="-0.1038" upper_limit="0.0021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD (n=69,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0884" lower_limit="-0.1398" upper_limit="-0.0371"/>
                    <measurement group_id="O2" value="-0.0878" lower_limit="-0.1649" upper_limit="-0.0107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Assessed Using the EQ-5D Visual Analogue Scale (VAS) Scores (Data Cutoff 20 December 2013)</title>
        <description>The participant was asked to rate their overall health on a 0-100 millimeter (mm) vertical scale, where the lowest endpoint=0 (labeled as worst imaginable health state) and the highest endpoint =100 (labeled as the best imaginable health state). The participant marked the line corresponding to their assessment and the distance from the bottom was measured in millimeters. A higher value indicated a better health state.</description>
        <time_frame>Baseline, during second-line treatment at Weeks 8 and 16 (4-week cycles) or Weeks 9 and 18 (3-week cycles) and at second-line PD (up to approximately 3 years)</time_frame>
        <population>ITT population; n=number of participants who completed the assessment at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Assessed Using the EQ-5D Visual Analogue Scale (VAS) Scores (Data Cutoff 20 December 2013)</title>
          <description>The participant was asked to rate their overall health on a 0-100 millimeter (mm) vertical scale, where the lowest endpoint=0 (labeled as worst imaginable health state) and the highest endpoint =100 (labeled as the best imaginable health state). The participant marked the line corresponding to their assessment and the distance from the bottom was measured in millimeters. A higher value indicated a better health state.</description>
          <population>ITT population; n=number of participants who completed the assessment at the specified timepoint.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (n=200,212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.5" lower_limit="64.1" upper_limit="69.0"/>
                    <measurement group_id="O2" value="63.4" lower_limit="60.8" upper_limit="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9 (n=123,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" lower_limit="66.4" upper_limit="72.1"/>
                    <measurement group_id="O2" value="66.5" lower_limit="63.7" upper_limit="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18 (n=75,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" lower_limit="63.3" upper_limit="71.3"/>
                    <measurement group_id="O2" value="66.4" lower_limit="63.2" upper_limit="69.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD (n=78,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.7" lower_limit="59.5" upper_limit="68.0"/>
                    <measurement group_id="O2" value="61.7" lower_limit="57.0" upper_limit="66.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in VAS Scores (Data Cutoff 20 December 2013)</title>
        <description>The participant was asked to rate their overall health on a 0-100 mm vertical scale, where the lowest endpoint = 0 (labeled as worst imaginable health state) and the highest endpoint =100 (labeled as the best imaginable health state). The participant marked the line corresponding to their assessment and the distance from the bottom was measured in millimeters. A negative value indicated a worsening of perceived quality of life and a positive value indicated an improvement of perceived quality of life.</description>
        <time_frame>Baseline, during second-line treatment at Weeks 8 and 16 (4-week cycles) or Weeks 9 and 18 (3-week cycles) and at second-line PD (up to approximately 3 years)</time_frame>
        <population>ITT population. Here, Number of participants analyzed = participants evaluable for this outcome measure and n=number of participants who completed the assessment at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in VAS Scores (Data Cutoff 20 December 2013)</title>
          <description>The participant was asked to rate their overall health on a 0-100 mm vertical scale, where the lowest endpoint = 0 (labeled as worst imaginable health state) and the highest endpoint =100 (labeled as the best imaginable health state). The participant marked the line corresponding to their assessment and the distance from the bottom was measured in millimeters. A negative value indicated a worsening of perceived quality of life and a positive value indicated an improvement of perceived quality of life.</description>
          <population>ITT population. Here, Number of participants analyzed = participants evaluable for this outcome measure and n=number of participants who completed the assessment at the specified timepoint.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8/9 (n=106,118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-4.8" upper_limit="0.9"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-1.4" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18 (n=66,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-4.7" upper_limit="4.3"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-1.6" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-line PD (n=70,69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" lower_limit="-9.1" upper_limit="-1.0"/>
                    <measurement group_id="O2" value="-1.3" lower_limit="-5.5" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Cancer Therapy-Breast (FACT-B) Scores (Data Cutoff 20 December 2013)</title>
        <description>The Functional Assessment of Cancer Therapy-Breast (FACT-B) is composed of 5 multi-item sections where participants responded to questions assessing symptoms (scale: 0-4; 0=&quot;not at all&quot; and 4=&quot;very much&quot;), as follows: physical well-being (PWB) (7 items, total score 0-28), social/family well-being (SWB) (7 items, total score 0-28), emotional well-being (EWB) (6 items, total score 0-24), functional well-being (FWB) (7 items, total score 0-28); and breast cancer score based on the additional concerns section of FACT-B (10 items, total score 0-40). The FACT-B Trial Outcomes Index (TOI) score=sum of PWB, FWB, and breast cancer score subscale scores (total score 0-96). The Functional Assessment of Cancer Therapy-General (FACT-G) total score=sum of PWB, SWB, EWB, and FWB subscales scores (total score 0-108). The FACT-B total score=sum of PWB, SWB, EWB, FWB, and breast cancer score subscales scores (total score 0-148). In all cases a higher value indicated a better perceived quality of life.</description>
        <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter until second-line PD (up to approximately 3 years)</time_frame>
        <population>ITT population. Here, Number of participants analyzed = participants evaluable for this outcome measure and n=number of participants who completed the questionnaire at the specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Cancer Therapy-Breast (FACT-B) Scores (Data Cutoff 20 December 2013)</title>
          <description>The Functional Assessment of Cancer Therapy-Breast (FACT-B) is composed of 5 multi-item sections where participants responded to questions assessing symptoms (scale: 0-4; 0=&quot;not at all&quot; and 4=&quot;very much&quot;), as follows: physical well-being (PWB) (7 items, total score 0-28), social/family well-being (SWB) (7 items, total score 0-28), emotional well-being (EWB) (6 items, total score 0-24), functional well-being (FWB) (7 items, total score 0-28); and breast cancer score based on the additional concerns section of FACT-B (10 items, total score 0-40). The FACT-B Trial Outcomes Index (TOI) score=sum of PWB, FWB, and breast cancer score subscale scores (total score 0-96). The Functional Assessment of Cancer Therapy-General (FACT-G) total score=sum of PWB, SWB, EWB, and FWB subscales scores (total score 0-108). The FACT-B total score=sum of PWB, SWB, EWB, FWB, and breast cancer score subscales scores (total score 0-148). In all cases a higher value indicated a better perceived quality of life.</description>
          <population>ITT population. Here, Number of participants analyzed = participants evaluable for this outcome measure and n=number of participants who completed the questionnaire at the specified timepoints.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL: PWB (n=215,222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.621" lower_limit="19.900" upper_limit="21.342"/>
                    <measurement group_id="O2" value="20.253" lower_limit="19.500" upper_limit="21.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: SWB (n=214,223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.722" lower_limit="20.028" upper_limit="21.416"/>
                    <measurement group_id="O2" value="20.674" lower_limit="19.923" upper_limit="21.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: EWB (n=215,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.847" lower_limit="14.176" upper_limit="15.519"/>
                    <measurement group_id="O2" value="15.062" lower_limit="14.419" upper_limit="15.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: FWB (n=215,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.091" lower_limit="15.289" upper_limit="16.894"/>
                    <measurement group_id="O2" value="15.726" lower_limit="14.951" upper_limit="16.502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Breast Cancer Score (n=210,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.986" lower_limit="24.103" upper_limit="25.869"/>
                    <measurement group_id="O2" value="24.388" lower_limit="23.578" upper_limit="25.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: FACT-B TOI (n=204,219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.677" lower_limit="59.658" upper_limit="63.696"/>
                    <measurement group_id="O2" value="60.277" lower_limit="58.365" upper_limit="62.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Total FACT-G Score (n=207,218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.169" lower_limit="69.919" upper_limit="74.419"/>
                    <measurement group_id="O2" value="71.864" lower_limit="69.786" upper_limit="73.942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Total FACT-B Score (n=201,218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.908" lower_limit="94.063" upper_limit="99.753"/>
                    <measurement group_id="O2" value="96.115" lower_limit="93.485" upper_limit="98.746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: PWB (n=129,138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.413" lower_limit="19.413" upper_limit="21.413"/>
                    <measurement group_id="O2" value="19.156" lower_limit="18.158" upper_limit="20.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: SWB (n=127,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.833" lower_limit="19.888" upper_limit="21.779"/>
                    <measurement group_id="O2" value="21.116" lower_limit="20.245" upper_limit="21.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: EWB (n=129,139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.943" lower_limit="15.070" upper_limit="16.815"/>
                    <measurement group_id="O2" value="16.671" lower_limit="15.900" upper_limit="17.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: FWB (n=129,139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.662" lower_limit="15.609" upper_limit="17.715"/>
                    <measurement group_id="O2" value="16.169" lower_limit="15.180" upper_limit="17.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: Breast Cancer Score (n=128,139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.276" lower_limit="25.188" upper_limit="27.364"/>
                    <measurement group_id="O2" value="25.884" lower_limit="24.928" upper_limit="26.839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: FACT-B TOI (n=126,136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.547" lower_limit="60.975" upper_limit="66.118"/>
                    <measurement group_id="O2" value="61.279" lower_limit="58.811" upper_limit="63.747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: Total FACT-G Score (n=122,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.255" lower_limit="71.212" upper_limit="77.299"/>
                    <measurement group_id="O2" value="73.393" lower_limit="70.603" upper_limit="76.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: Total FACT-B Score (n=123,134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.375" lower_limit="96.582" upper_limit="104.169"/>
                    <measurement group_id="O2" value="99.213" lower_limit="95.667" upper_limit="102.760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: PWB (n=83,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.733" lower_limit="20.721" upper_limit="22.744"/>
                    <measurement group_id="O2" value="19.629" lower_limit="18.571" upper_limit="20.688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: SWB (n=80,105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.930" lower_limit="19.855" upper_limit="22.006"/>
                    <measurement group_id="O2" value="20.843" lower_limit="19.829" upper_limit="21.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: EWB (n=80,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.330" lower_limit="16.260" upper_limit="18.400"/>
                    <measurement group_id="O2" value="16.806" lower_limit="15.961" upper_limit="17.650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: FWB (n=81,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.055" lower_limit="15.818" upper_limit="18.291"/>
                    <measurement group_id="O2" value="15.920" lower_limit="14.787" upper_limit="17.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: Breast Cancer (n=81,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.923" lower_limit="25.493" upper_limit="28.354"/>
                    <measurement group_id="O2" value="25.755" lower_limit="24.630" upper_limit="26.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: FACT-B TOI (n=78,105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.628" lower_limit="62.539" upper_limit="68.717"/>
                    <measurement group_id="O2" value="61.107" lower_limit="58.309" upper_limit="63.905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: Total FACT-G (n=78,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.794" lower_limit="73.269" upper_limit="80.318"/>
                    <measurement group_id="O2" value="73.269" lower_limit="70.116" upper_limit="76.421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: Total FACT-B (n=76,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.503" lower_limit="98.819" upper_limit="108.187"/>
                    <measurement group_id="O2" value="98.906" lower_limit="94.865" upper_limit="102.948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/27: PWB (n=48,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.940" lower_limit="20.599" upper_limit="23.282"/>
                    <measurement group_id="O2" value="18.965" lower_limit="17.515" upper_limit="20.416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/27: SWB (n=47,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.840" lower_limit="19.468" upper_limit="22.211"/>
                    <measurement group_id="O2" value="21.399" lower_limit="20.192" upper_limit="22.606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/27: EWB (n=45,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.098" lower_limit="15.719" upper_limit="18.477"/>
                    <measurement group_id="O2" value="16.438" lower_limit="15.411" upper_limit="17.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/27: FWB (n=45,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.244" lower_limit="16.754" upper_limit="19.734"/>
                    <measurement group_id="O2" value="16.051" lower_limit="14.861" upper_limit="17.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/27: Breast Cancer (n=46,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.067" lower_limit="24.146" upper_limit="27.988"/>
                    <measurement group_id="O2" value="24.632" lower_limit="23.231" upper_limit="26.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/27: FACT-B TOI (n=44,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.882" lower_limit="61.991" upper_limit="69.653"/>
                    <measurement group_id="O2" value="60.014" lower_limit="56.548" upper_limit="63.480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/27: Total FACT-G (n=44,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.305" lower_limit="74.166" upper_limit="82.443"/>
                    <measurement group_id="O2" value="73.083" lower_limit="69.365" upper_limit="76.801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/27: Total FACT-B (n=43,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.011" lower_limit="98.433" upper_limit="109.588"/>
                    <measurement group_id="O2" value="97.795" lower_limit="92.995" upper_limit="102.595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/36: PWB (n=26,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.949" lower_limit="21.427" upper_limit="24.471"/>
                    <measurement group_id="O2" value="19.686" lower_limit="18.121" upper_limit="21.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/36: SWB (n=25,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.140" lower_limit="20.433" upper_limit="23.847"/>
                    <measurement group_id="O2" value="21.222" lower_limit="19.645" upper_limit="22.798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/36: EWB (n=26,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.385" lower_limit="16.690" upper_limit="20.079"/>
                    <measurement group_id="O2" value="16.755" lower_limit="15.481" upper_limit="18.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/36: FWB (n=26,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.615" lower_limit="17.875" upper_limit="21.356"/>
                    <measurement group_id="O2" value="17.195" lower_limit="15.585" upper_limit="18.805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/36: Breast Cancer (n=26,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.568" lower_limit="27.722" upper_limit="31.415"/>
                    <measurement group_id="O2" value="26.163" lower_limit="24.457" upper_limit="27.869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/36: FACT-B TOI (n=26,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.132" lower_limit="68.549" upper_limit="75.716"/>
                    <measurement group_id="O2" value="63.017" lower_limit="59.199" upper_limit="66.836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/36: Total FACT-G (n=25,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.087" lower_limit="78.178" upper_limit="87.995"/>
                    <measurement group_id="O2" value="74.879" lower_limit="70.566" upper_limit="79.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/36: Total FACT-B (n=25,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.904" lower_limit="107.315" upper_limit="118.494"/>
                    <measurement group_id="O2" value="100.904" lower_limit="95.302" upper_limit="106.506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/45: PWB (n=20,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.215" lower_limit="20.583" upper_limit="23.847"/>
                    <measurement group_id="O2" value="20.630" lower_limit="18.820" upper_limit="22.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/45: SWB (n=21,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.658" lower_limit="17.955" upper_limit="21.361"/>
                    <measurement group_id="O2" value="20.915" lower_limit="19.146" upper_limit="22.685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/45: EWB (n=20,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.560" lower_limit="15.708" upper_limit="19.412"/>
                    <measurement group_id="O2" value="16.067" lower_limit="13.875" upper_limit="18.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/45: FWB (n=20,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.450" lower_limit="16.120" upper_limit="20.780"/>
                    <measurement group_id="O2" value="16.519" lower_limit="13.901" upper_limit="19.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/45: Breast Cancer (n=21,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.386" lower_limit="27.156" upper_limit="31.616"/>
                    <measurement group_id="O2" value="23.819" lower_limit="21.013" upper_limit="26.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/45: FACT-B TOI (n=19,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.750" lower_limit="63.981" upper_limit="73.518"/>
                    <measurement group_id="O2" value="60.967" lower_limit="55.065" upper_limit="66.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/45: Total FACT-G (n=19,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.955" lower_limit="71.480" upper_limit="82.430"/>
                    <measurement group_id="O2" value="75.235" lower_limit="68.901" upper_limit="81.568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/45: Total FACT-B (n=19,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.540" lower_limit="98.512" upper_limit="112.568"/>
                    <measurement group_id="O2" value="99.072" lower_limit="90.613" upper_limit="107.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/54: PWB (n=13,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.308" lower_limit="21.283" upper_limit="25.333"/>
                    <measurement group_id="O2" value="20.033" lower_limit="18.124" upper_limit="21.943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/54: SWB (n=13,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.740" lower_limit="18.953" upper_limit="22.527"/>
                    <measurement group_id="O2" value="20.450" lower_limit="18.310" upper_limit="22.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/54: EWB (n=13,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.308" lower_limit="17.522" upper_limit="21.093"/>
                    <measurement group_id="O2" value="17.270" lower_limit="15.494" upper_limit="19.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/54: FWB (n=13,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.538" lower_limit="16.586" upper_limit="20.491"/>
                    <measurement group_id="O2" value="16.268" lower_limit="13.949" upper_limit="18.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/54: Breast Cancer (n=13,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.912" lower_limit="26.879" upper_limit="30.945"/>
                    <measurement group_id="O2" value="26.237" lower_limit="22.842" upper_limit="29.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/54: Fact-B TOI (n=13,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.758" lower_limit="66.403" upper_limit="75.114"/>
                    <measurement group_id="O2" value="62.679" lower_limit="55.941" upper_limit="69.418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/54: Total FACT-G (n=13,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.894" lower_limit="76.424" upper_limit="87.363"/>
                    <measurement group_id="O2" value="74.162" lower_limit="67.865" upper_limit="80.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/54: Total FACT-B (n=13,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.806" lower_limit="104.704" upper_limit="116.908"/>
                    <measurement group_id="O2" value="100.399" lower_limit="91.294" upper_limit="109.503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/63: PWB (n=8,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.792" lower_limit="18.958" upper_limit="24.626"/>
                    <measurement group_id="O2" value="20.298" lower_limit="17.412" upper_limit="23.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/63: SWB (n=8,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.583" lower_limit="15.598" upper_limit="23.569"/>
                    <measurement group_id="O2" value="20.817" lower_limit="17.629" upper_limit="24.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/63: EWB (n=7,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.143" lower_limit="13.389" upper_limit="20.897"/>
                    <measurement group_id="O2" value="15.714" lower_limit="12.606" upper_limit="18.823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/63: FWB (n=7,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.143" lower_limit="13.876" upper_limit="20.410"/>
                    <measurement group_id="O2" value="16.476" lower_limit="12.633" upper_limit="20.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/63: Breast Cancer (n=8,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.240" lower_limit="23.931" upper_limit="32.548"/>
                    <measurement group_id="O2" value="25.459" lower_limit="21.407" upper_limit="29.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/63: FACT-B TOI (n=7,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.179" lower_limit="55.888" upper_limit="76.469"/>
                    <measurement group_id="O2" value="62.233" lower_limit="53.524" upper_limit="70.942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/63: Total FACT-G (n=6,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.667" lower_limit="58.381" upper_limit="88.952"/>
                    <measurement group_id="O2" value="73.305" lower_limit="62.863" upper_limit="83.746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/63: Total FACT-B (n=6,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.042" lower_limit="81.841" upper_limit="120.242"/>
                    <measurement group_id="O2" value="98.764" lower_limit="85.368" upper_limit="112.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64/72: PWB (n=7,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.857" lower_limit="17.376" upper_limit="26.338"/>
                    <measurement group_id="O2" value="21.889" lower_limit="19.569" upper_limit="24.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64/72: SWB (n=7,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.976" lower_limit="16.352" upper_limit="21.600"/>
                    <measurement group_id="O2" value="22.685" lower_limit="19.417" upper_limit="25.953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64/72: EWB (n=7,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.143" lower_limit="13.758" upper_limit="22.527"/>
                    <measurement group_id="O2" value="17.889" lower_limit="14.274" upper_limit="21.503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64/72: FWB (n=7,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.429" lower_limit="14.658" upper_limit="22.199"/>
                    <measurement group_id="O2" value="16.037" lower_limit="12.890" upper_limit="19.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64/72: Breast Cancer (n=7,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.464" lower_limit="22.941" upper_limit="31.988"/>
                    <measurement group_id="O2" value="26.889" lower_limit="22.584" upper_limit="31.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64/72: FACT-B TOI (n=7,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.750" lower_limit="56.306" upper_limit="79.194"/>
                    <measurement group_id="O2" value="64.815" lower_limit="56.516" upper_limit="73.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64/72: Total FACT-G (n=7,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.405" lower_limit="63.847" upper_limit="90.963"/>
                    <measurement group_id="O2" value="78.500" lower_limit="68.852" upper_limit="88.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64/72: Total FACT-B (n=7,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.869" lower_limit="87.586" upper_limit="122.152"/>
                    <measurement group_id="O2" value="105.389" lower_limit="92.415" upper_limit="118.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72/81: PWB (n=6,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.083" lower_limit="18.906" upper_limit="27.260"/>
                    <measurement group_id="O2" value="21.000" lower_limit="16.407" upper_limit="25.593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72/81: SWB (n=5,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.667" lower_limit="16.238" upper_limit="23.095"/>
                    <measurement group_id="O2" value="20.043" lower_limit="14.019" upper_limit="26.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72/81: EWB (n=6,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.500" lower_limit="13.476" upper_limit="21.524"/>
                    <measurement group_id="O2" value="18.114" lower_limit="14.130" upper_limit="22.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72/81: FWB (n=6,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.333" lower_limit="14.316" upper_limit="20.351"/>
                    <measurement group_id="O2" value="16.429" lower_limit="11.339" upper_limit="21.518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72/81: Breast Cancer (n=6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.597" lower_limit="24.421" upper_limit="32.774"/>
                    <measurement group_id="O2" value="25.333" lower_limit="20.250" upper_limit="30.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72/81: FACT-B TOI (n=6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.014" lower_limit="59.566" upper_limit="78.462"/>
                    <measurement group_id="O2" value="60.833" lower_limit="47.031" upper_limit="74.635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72/81: Total FACT-G (n=5,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.467" lower_limit="62.045" upper_limit="90.889"/>
                    <measurement group_id="O2" value="75.586" lower_limit="57.141" upper_limit="94.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72/81: Total FACT-B (n=5,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.117" lower_limit="88.146" upper_limit="124.087"/>
                    <measurement group_id="O2" value="97.211" lower_limit="73.196" upper_limit="121.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/90: PWB (n=2,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.250" lower_limit="-32.634" upper_limit="71.134"/>
                    <measurement group_id="O2" value="18.000" lower_limit="2.487" upper_limit="33.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/90: SWB (n=2,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.375" lower_limit="7.257" upper_limit="29.493"/>
                    <measurement group_id="O2" value="19.944" lower_limit="3.434" upper_limit="36.455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/90: EWB (n=2,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.000" lower_limit="-49.531" upper_limit="77.531"/>
                    <measurement group_id="O2" value="15.733" lower_limit="-3.285" upper_limit="34.752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/90: FWB (n=2,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.000" lower_limit="-35.825" upper_limit="65.825"/>
                    <measurement group_id="O2" value="12.333" lower_limit="-1.348" upper_limit="26.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/90: Breast Cancer (n=2,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.667" lower_limit="0.490" upper_limit="42.844"/>
                    <measurement group_id="O2" value="25.000" lower_limit="14.172" upper_limit="35.828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/90: FACT-B TOI (n=2,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.917" lower_limit="-67.969" upper_limit="179.802"/>
                    <measurement group_id="O2" value="55.333" lower_limit="20.085" upper_limit="90.581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/90: Total FACT-G (n=2,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.625" lower_limit="-110.732" upper_limit="243.982"/>
                    <measurement group_id="O2" value="66.011" lower_limit="2.191" upper_limit="129.831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/90: Total FACT-B (n=2,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.292" lower_limit="-110.243" upper_limit="286.826"/>
                    <measurement group_id="O2" value="91.011" lower_limit="20.313" upper_limit="161.709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88/99: PWB (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="22.000">Standard deviation (SD) not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88/99: SWB (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="23.333">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88/99: EWB (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="20.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88/99: FWB (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="21.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88/99: Breast Cancer (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="35.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88/99: FACT-B TOI (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="78.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88/99: Total FACT-G (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="86.333">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88/99: Total FACT-B (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="121.333">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96/108: PWB (n=2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.000">SD not calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="22.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96/108: SWB (n=2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.383" lower_limit="-3.782" upper_limit="52.549"/>
                    <measurement group_id="O2" value="21.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96/108: EWB (n=2,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.000" lower_limit="9.294" upper_limit="34.706"/>
                    <measurement group_id="O2" value="18.000" lower_limit="-7.412" upper_limit="43.412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96/108: FWB (n=2,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.083" lower_limit="7.318" upper_limit="34.848"/>
                    <measurement group_id="O2" value="10.500" lower_limit="-46.678" upper_limit="67.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96/108: Breast Cancer (n=2,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.389" lower_limit="-2.788" upper_limit="63.566"/>
                    <measurement group_id="O2" value="24.500" lower_limit="-7.266" upper_limit="56.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96/108: FACT-B TOI (n=2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.472" lower_limit="58.060" upper_limit="96.884"/>
                    <measurement group_id="O2" value="59.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96/108: Total FACT-G (n=2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.467" lower_limit="38.830" upper_limit="148.103"/>
                    <measurement group_id="O2" value="74.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96/108: Total FACT-B (n=2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.856" lower_limit="102.396" upper_limit="145.315"/>
                    <measurement group_id="O2" value="96.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/117: PWB (n=1,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.000">SD not calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="21.333" lower_limit="17.539" upper_limit="25.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/117: SWB (n=1,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.600">SD not calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="20.5000" lower_limit="14.147" upper_limit="26.853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/117: EWB (n=1,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.000">SD not calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="18.000" lower_limit="6.616" upper_limit="29.384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/117: FWB (n=1,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.000">SD not calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="11.000" lower_limit="-1.908" upper_limit="23.908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/117: Breast Cancer (n=1,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.143">SD not calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="28.000" lower_limit="19.395" upper_limit="36.605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/117: FACT-B TOI (n=1,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.143">SD not calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="60.333" lower_limit="45.778" upper_limit="74.889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/117: Total FACT-G (n=1,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.600">SD not calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="70.500" lower_limit="-50.209" upper_limit="191.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/117: Total FACT-B (n=1,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.743">SD not calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="100.500" lower_limit="-20.209" upper_limit="221.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112/126: PWB (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="14.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112/126: SWB (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="15.400">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112/126: EWB (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="15.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112/126: FWB (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="11.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112/126: Breast Cancer (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="20.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112/126: FACT-B TOI (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="45.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112/126: Total FACT-G (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="55.400">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112/126: Total FACT-B (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="75.400">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-Line PD: PWB (n=89,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.086" lower_limit="17.873" upper_limit="20.299"/>
                    <measurement group_id="O2" value="17.412" lower_limit="15.977" upper_limit="18.846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-Line PD: SWB (n=88,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.623" lower_limit="19.456" upper_limit="21.790"/>
                    <measurement group_id="O2" value="21.487" lower_limit="20.335" upper_limit="22.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-Line PD: EWB (n=88,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.111" lower_limit="14.102" upper_limit="16.121"/>
                    <measurement group_id="O2" value="14.175" lower_limit="12.872" upper_limit="15.478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-Line PD: FWB (n=88,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.447" lower_limit="14.122" upper_limit="16.772"/>
                    <measurement group_id="O2" value="15.235" lower_limit="13.877" upper_limit="16.593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-Line PD: Breast Cancer (n=85,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.978" lower_limit="23.602" upper_limit="26.354"/>
                    <measurement group_id="O2" value="24.445" lower_limit="22.989" upper_limit="25.901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-Line PD: FACT-B TOI (n=84,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.230" lower_limit="56.033" upper_limit="62.428"/>
                    <measurement group_id="O2" value="57.002" lower_limit="53.234" upper_limit="60.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-Line PD: Total FACT-G (n=86,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.829" lower_limit="66.264" upper_limit="73.393"/>
                    <measurement group_id="O2" value="68.485" lower_limit="64.384" upper_limit="72.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-Line PD: Total FACT-B (n=82,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.930" lower_limit="90.240" upper_limit="99.619"/>
                    <measurement group_id="O2" value="92.983" lower_limit="87.645" upper_limit="98.320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FACT-B Scores (Data Cutoff 20 December 2013)</title>
        <description>The FACT-B is composed of 5 multi-item sections where participants responded to questions assessing symptoms (scale: 0-4; 0=&quot;not at all&quot; and 4=&quot;very much&quot;), as follows: PWB (7 items, total score 0-28), SWB (7 items, total score 0-28), EWB (6 items, total score 0-24), FWB (7 items, total score 0-28); and breast cancer score based on the additional concerns section of FACT-B (10 items, total score 0-40). The FACT-B TOI score=sum of PWB, FWB, and breast cancer score subscale scores (total score 0-96). The FACT-G total score=sum of PWB, SWB, EWB, and FWB subscales scores (total score 0-108). The FACT-B total score=sum of PWB, SWB, EWB, FWB, and breast cancer score subscale scores (total score 0-148). In all cases a higher value indicated a better perceived quality of life.</description>
        <time_frame>Baseline (≤28 days after randomization), every 8-9 weeks thereafter until second-line PD (up to approximately 3 years)</time_frame>
        <population>ITT population. Here, Number of participants analyzed = participants evaluable for this outcome measure and n=number of participants who completed the assessment at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FACT-B Scores (Data Cutoff 20 December 2013)</title>
          <description>The FACT-B is composed of 5 multi-item sections where participants responded to questions assessing symptoms (scale: 0-4; 0=&quot;not at all&quot; and 4=&quot;very much&quot;), as follows: PWB (7 items, total score 0-28), SWB (7 items, total score 0-28), EWB (6 items, total score 0-24), FWB (7 items, total score 0-28); and breast cancer score based on the additional concerns section of FACT-B (10 items, total score 0-40). The FACT-B TOI score=sum of PWB, FWB, and breast cancer score subscale scores (total score 0-96). The FACT-G total score=sum of PWB, SWB, EWB, and FWB subscales scores (total score 0-108). The FACT-B total score=sum of PWB, SWB, EWB, FWB, and breast cancer score subscale scores (total score 0-148). In all cases a higher value indicated a better perceived quality of life.</description>
          <population>ITT population. Here, Number of participants analyzed = participants evaluable for this outcome measure and n=number of participants who completed the assessment at the specified timepoint.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8/9: PWB (n=118,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.281" lower_limit="-2.219" upper_limit="-0.344"/>
                    <measurement group_id="O2" value="-1.289" lower_limit="-2.239" upper_limit="-0.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: SWB (n=116,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.356" lower_limit="-0.283" upper_limit="0.994"/>
                    <measurement group_id="O2" value="0.707" lower_limit="-0.226" upper_limit="1.640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: EWB (n=116,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.408" lower_limit="-0.274" upper_limit="1.089"/>
                    <measurement group_id="O2" value="1.024" lower_limit="0.314" upper_limit="1.734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: FWB (n=117,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.226" lower_limit="-1.043" upper_limit="0.591"/>
                    <measurement group_id="O2" value="-0.240" lower_limit="-1.027" upper_limit="0.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: Breast Cancer Score (n=113,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.228" lower_limit="-0.659" upper_limit="1.116"/>
                    <measurement group_id="O2" value="0.950" lower_limit="0.121" upper_limit="1.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: FACT-B TOI (n=110,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.361" lower_limit="-3.295" upper_limit="0.573"/>
                    <measurement group_id="O2" value="-0.357" lower_limit="-2.407" upper_limit="1.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: Total FACT-G Score (n=110,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.760" lower_limit="-2.920" upper_limit="1.399"/>
                    <measurement group_id="O2" value="0.369" lower_limit="-1.945" upper_limit="2.684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8/9: Total FACT-B Score (n=108,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.728" lower_limit="-3.332" upper_limit="1.876"/>
                    <measurement group_id="O2" value="1.342" lower_limit="-1.544" upper_limit="4.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: PWB (n=77,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.294" lower_limit="-0,733" upper_limit="1.322"/>
                    <measurement group_id="O2" value="-1.823" lower_limit="-2.871" upper_limit="-0.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: SWB (n=74,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.443" lower_limit="-1.411" upper_limit="0.525"/>
                    <measurement group_id="O2" value="0.359" lower_limit="-0.678" upper_limit="1.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: EWB (n=73,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.197" lower_limit="0.415" upper_limit="1.979"/>
                    <measurement group_id="O2" value="0.921" lower_limit="0.186" upper_limit="1.657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: FWB (n=75,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.548" lower_limit="-1.666" upper_limit="0.570"/>
                    <measurement group_id="O2" value="-0.517" lower_limit="-1.422" upper_limit="0.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: Breast Cancer (n=72,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.578" lower_limit="-0.658" upper_limit="1.815"/>
                    <measurement group_id="O2" value="0.546" lower_limit="-0.423" upper_limit="1.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: FACT-TOI (n=68,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.483" lower_limit="-3.149" upper_limit="2.183"/>
                    <measurement group_id="O2" value="-1.732" lower_limit="-4.049" upper_limit="0.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: Total FACT-G (n=71,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019" lower_limit="-2.970" upper_limit="2.931"/>
                    <measurement group_id="O2" value="-0.836" lower_limit="-3.494" upper_limit="1.821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16/18: Total Fact-B (n=66,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.007" lower_limit="-3.744" upper_limit="3.730"/>
                    <measurement group_id="O2" value="-0.127" lower_limit="-3.421" upper_limit="3.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/27: PWB (n=44,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.181" lower_limit="-1.236" upper_limit="1.598"/>
                    <measurement group_id="O2" value="-1.996" lower_limit="-3.306" upper_limit="-0.685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/27: SWB (n=44,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.193" lower_limit="-1.490" upper_limit="1.104"/>
                    <measurement group_id="O2" value="1.375" lower_limit="-0.001" upper_limit="2.750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/27: EWB (n=42,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.867" lower_limit="-0.101" upper_limit="1.834"/>
                    <measurement group_id="O2" value="1.217" lower_limit="0.366" upper_limit="2.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/27: FWB (n=42,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.119" lower_limit="-1.405" upper_limit="1.643"/>
                    <measurement group_id="O2" value="0.056" lower_limit="-1.053" upper_limit="1.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/27: Breast Cancer (n=40,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.038" lower_limit="-1.723" upper_limit="1.647"/>
                    <measurement group_id="O2" value="0.078" lower_limit="-1.106" upper_limit="1.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/27: FACT-B TOI (n=38,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.221" lower_limit="-3.411" upper_limit="3.853"/>
                    <measurement group_id="O2" value="-1.573" lower_limit="-4.383" upper_limit="1.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/27: Total FACT-G (n=40,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.764" lower_limit="-3.066" upper_limit="4.595"/>
                    <measurement group_id="O2" value="0.817" lower_limit="-2.497" upper_limit="4.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/27: Total FACT-B (n=37,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.793" lower_limit="-4.106" upper_limit="5.693"/>
                    <measurement group_id="O2" value="1.157" lower_limit="-2.828" upper_limit="5.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/36: PWB (n=25,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.880" lower_limit="-0.913" upper_limit="2.673"/>
                    <measurement group_id="O2" value="-1.235" lower_limit="-2.799" upper_limit="0.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/36: SWB (n=24,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.388" lower_limit="-1.754" upper_limit="0.979"/>
                    <measurement group_id="O2" value="1.036" lower_limit="-1.209" upper_limit="3.281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/36: EWB (n=25,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.064" lower_limit="-0.298" upper_limit="2.426"/>
                    <measurement group_id="O2" value="1.555" lower_limit="0.204" upper_limit="2.906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/36: FWB (n=25,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.380" lower_limit="-0.103" upper_limit="2.863"/>
                    <measurement group_id="O2" value="1.635" lower_limit="-0.201" upper_limit="3.471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/36: Breast Cancer (n=23,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.928" lower_limit="-1.916" upper_limit="3.771"/>
                    <measurement group_id="O2" value="1.278" lower_limit="-0.435" upper_limit="2.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/36: FACT-B TOI (n=23,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.123" lower_limit="-1.390" upper_limit="7.637"/>
                    <measurement group_id="O2" value="1.471" lower_limit="-2.522" upper_limit="5.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/36: Total FACT-G (n=24,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.617" lower_limit="-1.313" upper_limit="6.547"/>
                    <measurement group_id="O2" value="3.197" lower_limit="-1.346" upper_limit="7.740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/36: Total FACT-B (n=22,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.529" lower_limit="-2.074" upper_limit="9.132"/>
                    <measurement group_id="O2" value="3.896" lower_limit="-1.579" upper_limit="9.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/45: PWB (n=18,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.137" lower_limit="-2.051" upper_limit="2.325"/>
                    <measurement group_id="O2" value="-0.680" lower_limit="-2.930" upper_limit="1.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/45: SWB (n=19,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.589" lower_limit="-2.436" upper_limit="1.259"/>
                    <measurement group_id="O2" value="0.951" lower_limit="-1.590" upper_limit="3.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/45: EWB (n=18,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.200" lower_limit="-1.598" upper_limit="1.998"/>
                    <measurement group_id="O2" value="1.048" lower_limit="-0.658" upper_limit="2.754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/45: FWB (n=18,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.417" lower_limit="-0.562" upper_limit="3.395"/>
                    <measurement group_id="O2" value="0.857" lower_limit="-0.893" upper_limit="2.608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/45: Breast Cancer (n=18,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.395" lower_limit="-1.268" upper_limit="4.058"/>
                    <measurement group_id="O2" value="0.444" lower_limit="-2.358" upper_limit="3.247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/45: FACT-B TOI (n=16,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.432" lower_limit="-2.496" upper_limit="7.360"/>
                    <measurement group_id="O2" value="0.622" lower_limit="-4.688" upper_limit="5.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/45: Total FACT-G (n=17,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.444" lower_limit="-3.342" upper_limit="6.231"/>
                    <measurement group_id="O2" value="2.432" lower_limit="-3.035" upper_limit="7.899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/45: Total FACT-B (n=16,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.916" lower_limit="-3.950" upper_limit="7.782"/>
                    <measurement group_id="O2" value="2.673" lower_limit="-4.258" upper_limit="9.603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/54: PWB (n=13,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.295" lower_limit="-2.037" upper_limit="4.627"/>
                    <measurement group_id="O2" value="-1.833" lower_limit="-3.721" upper_limit="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/54: SWB (n=13,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.529" lower_limit="-0.316" upper_limit="3.375"/>
                    <measurement group_id="O2" value="2.008" lower_limit="-1.083" upper_limit="5.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/54: EWB (n=13,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.492" lower_limit="0.492" upper_limit="2.492"/>
                    <measurement group_id="O2" value="1.710" lower_limit="-0.183" upper_limit="3.603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/54: FWB (n=13,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.269" lower_limit="0.174" upper_limit="4.365"/>
                    <measurement group_id="O2" value="1.592" lower_limit="-0.872" upper_limit="4.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/54: Breast Cancer (n=12,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.599" lower_limit="-1.714" upper_limit="2.912"/>
                    <measurement group_id="O2" value="1.897" lower_limit="-0.463" upper_limit="4.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/54: FACT-B TOI (n=12,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.044" lower_limit="-2.832" upper_limit="10.919"/>
                    <measurement group_id="O2" value="1.656" lower_limit="-3.691" upper_limit="7.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/54: Total FACT-G (n=13,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.586" lower_limit="1.392" upper_limit="11.780"/>
                    <measurement group_id="O2" value="3.477" lower_limit="-2.596" upper_limit="9.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/54: Total FACT-B (n=12,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.067" lower_limit="0.241" upper_limit="13.894"/>
                    <measurement group_id="O2" value="5.374" lower_limit="-2.391" upper_limit="13.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/63: PWB (n=8,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.063" lower_limit="-6.094" upper_limit="1.969"/>
                    <measurement group_id="O2" value="-0.526" lower_limit="-3.996" upper_limit="2.944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/63: SWB (n=8,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.500" lower_limit="-5.699" upper_limit="2.699"/>
                    <measurement group_id="O2" value="3.033" lower_limit="-1.729" upper_limit="7.796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/63: EWB (n=7,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.857" lower_limit="-2.781" upper_limit="4.495"/>
                    <measurement group_id="O2" value="0.954" lower_limit="-2.190" upper_limit="4.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/63: FWB (n=7,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-4.835" upper_limit="4.835"/>
                    <measurement group_id="O2" value="5.654" lower_limit="0.511" upper_limit="10.797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/63: Breast Cancer (n=8,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.830" lower_limit="-6.133" upper_limit="4.474"/>
                    <measurement group_id="O2" value="1.675" lower_limit="-1.291" upper_limit="4.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/63: FACT-B TOI (n=7,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.591" lower_limit="-17.803" upper_limit="10.621"/>
                    <measurement group_id="O2" value="6.803" lower_limit="1.093" upper_limit="14.699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/63: Total FACT-G (n=6,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.083" lower_limit="-22.930" upper_limit="14.764"/>
                    <measurement group_id="O2" value="9.115" lower_limit="-3.820" upper_limit="22.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/63: Total FACT-B (n=6,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.301" lower_limit="-29.740" upper_limit="19.138"/>
                    <measurement group_id="O2" value="10.791" lower_limit="-3.114" upper_limit="24.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64/72: PWB (n=7,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-6.733" upper_limit="6.733"/>
                    <measurement group_id="O2" value="0.926" lower_limit="-1.491" upper_limit="3.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64/72: SWB (n=7,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.014" lower_limit="-5.182" upper_limit="1.154"/>
                    <measurement group_id="O2" value="3.570" lower_limit="-1.034" upper_limit="8.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64/72: EWB (n=7,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.057" lower_limit="-3.537" upper_limit="3.423"/>
                    <measurement group_id="O2" value="3.667" lower_limit="-0.630" upper_limit="7.964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64/72: FWB (n=7,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.214" lower_limit="-4.531" upper_limit="4.959"/>
                    <measurement group_id="O2" value="3.222" lower_limit="-2.143" upper_limit="8.588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64/72: Breast Cancer (n=7,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.298" lower_limit="-7.507" upper_limit="2.912"/>
                    <measurement group_id="O2" value="3.086" lower_limit="-1.361" upper_limit="7.534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64/72: FACT-B TOI (n=7,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.083" lower_limit="-17.130" upper_limit="12.963"/>
                    <measurement group_id="O2" value="7.235" lower_limit="-3.624" upper_limit="18.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64/72: Total FACT-G (n=7,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.857" lower_limit="-17.855" upper_limit="14.140"/>
                    <measurement group_id="O2" value="11.385" lower_limit="-3.116" upper_limit="25.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64/72: Total FACT-B (n=7,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.155" lower_limit="-24.302" upper_limit="15.993"/>
                    <measurement group_id="O2" value="14.472" lower_limit="-4.192" upper_limit="33.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72/81: PWB (n=5,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.133" lower_limit="-6.045" upper_limit="10.311"/>
                    <measurement group_id="O2" value="-0.429" lower_limit="-3.965" upper_limit="3.108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72/81: SWB (n=4,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.208" lower_limit="-5.126" upper_limit="2.710"/>
                    <measurement group_id="O2" value="6.829" lower_limit="-3.189" upper_limit="16.846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72/81: EWB (n=5,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.600" lower_limit="-5.042" upper_limit="3.842"/>
                    <measurement group_id="O2" value="4.686" lower_limit="-0.608" upper_limit="9.979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72/81: FWB (n=5,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-5.341" upper_limit="5.341"/>
                    <measurement group_id="O2" value="7.381" lower_limit="-1.169" upper_limit="15.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72/81: Breast Cancer (n=5,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.461" lower_limit="-6.531" upper_limit="5.609"/>
                    <measurement group_id="O2" value="3.667" lower_limit="-3.410" upper_limit="10.743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72/81: FACT-B TOI (n=5,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.672" lower_limit="-12.563" upper_limit="15.907"/>
                    <measurement group_id="O2" value="8.278" lower_limit="-7.450" upper_limit="24.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72/81: Total FACT-G (n=4,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.167" lower_limit="-22.161" upper_limit="21.828"/>
                    <measurement group_id="O2" value="18.467" lower_limit="-1.867" upper_limit="38.801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72/81: Total FACT-B (n=4,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.174" lower_limit="-23.085" upper_limit="25.432"/>
                    <measurement group_id="O2" value="16.906" lower_limit="-9.207" upper_limit="43.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/90: PWB (n=2,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.750" lower_limit="-30.221" upper_limit="22.721"/>
                    <measurement group_id="O2" value="-3.000" lower_limit="-11.605" upper_limit="5.605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/90: SWB (n=2,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.875" lower_limit="-34.229" upper_limit="32.479"/>
                    <measurement group_id="O2" value="7.344" lower_limit="-9.614" upper_limit="24.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/90: EWB (n=2,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.000" lower_limit="-42.119" upper_limit="34.119"/>
                    <measurement group_id="O2" value="4.733" lower_limit="-18.466" upper_limit="27.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/90: FWB (n=2,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.000" lower_limit="-64.531" upper_limit="62.531"/>
                    <measurement group_id="O2" value="2.556" lower_limit="-9.165" upper_limit="14.276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/90: Breast Cancer (n=2,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.833" lower_limit="-29.128" upper_limit="17.461"/>
                    <measurement group_id="O2" value="3.667" lower_limit="-11.512" upper_limit="18.845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/90: FACT-B TOI (n=2,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.583" lower_limit="-77.291" upper_limit="56.124"/>
                    <measurement group_id="O2" value="3.222" lower_limit="-30.212" upper_limit="36.657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/90: Total FACT-G (n=2,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.625" lower_limit="-171.100" upper_limit="151.850"/>
                    <measurement group_id="O2" value="11.633" lower_limit="-41.554" upper_limit="64.821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/90: Total FACT-B (n=2,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.458" lower_limit="-153.638" upper_limit="122.722"/>
                    <measurement group_id="O2" value="15.300" lower_limit="-48.177" upper_limit="78.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88/99: PWB (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="-6.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88/99: SWB (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="23.333">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88/99: EWB (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="0.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88/99: FWB (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="21.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88/99: Breast Cancer (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="3.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88/99: FACT TOI (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="18.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88/99: Total FACT-G (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="38.333">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88/99: Total FACT-B (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="41.333">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96/108: PWB (n=2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.333" lower_limit="-51.962" upper_limit="66.629"/>
                    <measurement group_id="O2" value="-3.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96/108: SWB (n=2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.183" lower_limit="-23.441" upper_limit="27.808"/>
                    <measurement group_id="O2" value="1.400">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96/108: EWB (n=2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-12.706" upper_limit="12.706"/>
                    <measurement group_id="O2" value="6.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96/108: FWB (n=2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.583" lower_limit="-13.535" upper_limit="26.701"/>
                    <measurement group_id="O2" value="-1.333">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96/108: Breast Cancer (n=2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.167" lower_limit="-41.305" upper_limit="47.638"/>
                    <measurement group_id="O2" value="-3.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96/108: FACT-B TOI (n=2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.083" lower_limit="11.789" upper_limit="22.378"/>
                    <measurement group_id="O2" value="-7.333">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96/108: Total FACT-G (n=2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.100" lower_limit="15.253" upper_limit="16.947"/>
                    <measurement group_id="O2" value="3.067">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96/108: Total FACT-B (n=2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.267" lower_limit="-24.358" upper_limit="62.891"/>
                    <measurement group_id="O2" value="0.067">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/117: PWB (n=1,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.667">SD not calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="-2.000" lower_limit="-40.119" upper_limit="36.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/117: SWB (n=1,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.200">SD not calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="8.800">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/117: EWB (n=1,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000">SD not calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="10.000" lower_limit="-28.119" upper_limit="48.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/117: FWB (n=1,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.000">SD not calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="2.333" lower_limit="-56.962" upper_limit="61.629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/117: Breast Cancer (n=1,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.032">SD not calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="4.000" lower_limit="-59.531" upper_limit="67.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/117: FACT-B TOI (n=1,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.698">SD not calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="4.333" lower_limit="-156.612" upper_limit="165.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/117: Total FACT-G (n=1,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.867">SD not calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="29.800">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/117: Total GACT-B (n=1,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.898">SD not calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="38.800">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112/126: PWB (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="-11.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112/126: SWB (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="-4.200">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112/126: EWB (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="5.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112/126: FWB (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="-5.333">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112/126: Breast Cancer (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="-5.000">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112/126: FACT-B TOI (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="-21.333">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112/126: Total FACT-G (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="-15.533">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112/126: Total FACT-B (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Zero participants analyzed.</measurement>
                    <measurement group_id="O2" value="-20.533">SD not calculated as only 1 participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-Line PD: PWB (n=81,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.871" lower_limit="-1.916" upper_limit="0.174"/>
                    <measurement group_id="O2" value="-2.507" lower_limit="-3.783" upper_limit="-1.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-Line PD: SWB (n=80,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.106" lower_limit="-0.902" upper_limit="0.690"/>
                    <measurement group_id="O2" value="-0.766" lower_limit="-1.788" upper_limit="0.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-Line PD: EWB (n=80,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.440" lower_limit="-1.553" upper_limit="0.673"/>
                    <measurement group_id="O2" value="-0.508" lower_limit="-1.562" upper_limit="0.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-Line PD: FWB (n=80,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.415" lower_limit="-2.590" upper_limit="-0.239"/>
                    <measurement group_id="O2" value="-0.773" lower_limit="-1.809" upper_limit="0.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-Line PD: Breast Cancer (n=77,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.120" lower_limit="-1.182" upper_limit="1.421"/>
                    <measurement group_id="O2" value="0.241" lower_limit="-0.878" upper_limit="1.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-Line PD: FACT-B TOI (n=74,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.311" lower_limit="-5.070" upper_limit="0.447"/>
                    <measurement group_id="O2" value="-3.003" lower_limit="-5.734" upper_limit="-0.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-Line PD: Total FACT-G (n=76,74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.771" lower_limit="-5.902" upper_limit="0.361"/>
                    <measurement group_id="O2" value="-4.702" lower_limit="-7.941" upper_limit="-1.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-Line PD: Total FACT-B (n=72,74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.719" lower_limit="-6.633" upper_limit="1.195"/>
                    <measurement group_id="O2" value="-4.440" lower_limit="-8.515" upper_limit="-0.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 12</title>
        <description>Second­line PFS was defined as the time from randomization to PD or death due to any cause during their second­line of treatment with bevacizumab and/or chemotherapy, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without secondline PD or death were censored at the date of last tumor assessment where non­progression was documented.</description>
        <time_frame>Month 12</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 12</title>
          <description>Second­line PFS was defined as the time from randomization to PD or death due to any cause during their second­line of treatment with bevacizumab and/or chemotherapy, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without secondline PD or death were censored at the date of last tumor assessment where non­progression was documented.</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="12.3" upper_limit="22.2"/>
                    <measurement group_id="O2" value="24.2" lower_limit="19.0" upper_limit="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 18</title>
        <description>Second­line PFS was defined as the time from randomization to PD or death due to any cause during their secondline of treatment with bevacizumab and/or chemotherapy, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second­line PD or death were censored at the date of last tumor assessment where non­progression was documented.</description>
        <time_frame>Month 18</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 18</title>
          <description>Second­line PFS was defined as the time from randomization to PD or death due to any cause during their secondline of treatment with bevacizumab and/or chemotherapy, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second­line PD or death were censored at the date of last tumor assessment where non­progression was documented.</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" lower_limit="6.4" upper_limit="14.3"/>
                    <measurement group_id="O2" value="11.0" lower_limit="7.4" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 24</title>
        <description>Second­line PFS was defined as the time from randomization to PD or death due to any cause during their second­line of treatment with bevacizumab and/or chemotherapy, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second­line PD or death were censored at the date of last tumor assessment where non­progression was documented.</description>
        <time_frame>Month 24</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>CT Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
          <group group_id="O2">
            <title>CT+BV Arm</title>
            <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 24</title>
          <description>Second­line PFS was defined as the time from randomization to PD or death due to any cause during their second­line of treatment with bevacizumab and/or chemotherapy, whichever occurred first. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second­line PD or death were censored at the date of last tumor assessment where non­progression was documented.</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="3.6" upper_limit="10.2"/>
                    <measurement group_id="O2" value="6.5" lower_limit="3.7" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to approximately 4 years.</time_frame>
      <desc>All randomized participants who received at least 1 dose of bevacizumab and/or chemotherapy were included in the analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>CT Arm</title>
          <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
        </group>
        <group group_id="E2">
          <title>CT+BV Arm</title>
          <description>Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, until the maximum cumulative dose of anthracycline was reached, or end of study (24 months after randomization of the last participant). Upon second-line disease progression participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator’s site plus bevacizumab, 15 mg/kg, IV, every 3 weeks, or 10 mg/kg, IV, every 2 weeks until disease progression, unacceptable toxicity, participant request for withdrawal, or end of study. Upon subsequent disease progression participants received treatment according the standard of care of the treatment site until end of study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Cardiotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Patient-device incompatibility</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Injection site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Biopsy liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stoke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Postrenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Salpingo-oophorectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Large intestine anastomosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Embolism arterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="218" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffman-LaRoche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

